Patents by Inventor Yael Langut
Yael Langut has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11912747Abstract: Described herein are recombinant chimeric proteins comprising a double stranded RNA (dsRNA) binding domain and a cancer-cell targeting domain for targeting of dsRNA to cancer cells. Methods of use of the described chimeric proteins are also provided herein.Type: GrantFiled: December 15, 2016Date of Patent: February 27, 2024Assignee: TARGIMMUNE THERAPEUTICS AGInventors: Alexander Levitzki, Yael Langut
-
Publication number: 20240033364Abstract: The present invention relates to a polyplex for use in the treatment of castration resistant prostate cancer (CRPC) comprising a double stranded RNA (dsRNA) and a polymeric conjugate, wherein said polymeric conjugate consists of a linear polyethyleneimine (LPEI), one or more polyethylene glycol (PEG) moieties, one or more linkers and one or more targeting moieties, wherein said LPEI is covalently bound to one or more PEG moieties and each of said one or more PEG moieties is conjugated via one of the one or more linkers to one of the one or more targeting moieties, wherein each of said one or more targeting moieties is capable of binding to a cancer antigen, and wherein said cancer antigen is prostate surface membrane antigen (PSMA). Further, the invention relates to a pharmaceutical composition for use in the treatment of CRPC.Type: ApplicationFiled: May 12, 2023Publication date: February 1, 2024Inventors: Esteban POMBO-VILLAR, Alexander LEVITZKI, Yael LANGUT, Maya ZIGLER, Alexei SHIR, Eric KITAS
-
Patent number: 11679160Abstract: The present invention relates to a polyplex for use in the treatment of castration resistant prostate cancer (CRPC) comprising a double stranded RNA (dsRNA) and a polymeric conjugate, wherein said polymeric conjugate consists of a linear polyethyleneimine (LPEl), one or more polyethylene glycol (PEG) moieties, one or more linkers and one or more targeting moieties, wherein said LPEl is covalently bound to one or more PEG moieties and each of said one or more PEG moieties is conjugated via one of the one or more linkers to one of the one or more targeting moieties, wherein each of said one or more targeting moieties is capable of binding to a cancer antigen, and wherein said cancer antigen is prostate surface membrane antigen (PSMA). Further, the invention relates to a pharmaceutical composition for use in the treatment of CRPC.Type: GrantFiled: September 27, 2018Date of Patent: June 20, 2023Assignee: TARGIMMUNE THERAPEUTICS AGInventors: Esteban Pombo-Villar, Alexander Levitzki, Yael Langut, Maya Zigler, Alexei Shir, Eric Kitas
-
Publication number: 20220339189Abstract: A method of treating cancer may include administering a polyplex of a double stranded RNA and a polymeric conjugate. The polymeric conjugate may consist of a linear polyethyleneimine covalently linked to one or more polyethylene glycol (PEG) moieties. Each PEG moiety may be conjugated via a linker to a targeting moiety capable of binding to a cancer antigen.Type: ApplicationFiled: March 2, 2022Publication date: October 27, 2022Inventors: Alex Levitzki, Salim Joubran, Alexei Shir, Maya Zigler, Alaa Talhami, Yael Langut
-
Publication number: 20220213158Abstract: Described herein are recombinant chimeric proteins comprising a double stranded RNA (dsRNA) binding domain and a cancer-cell targeting domain for targeting of dsRNA to cancer cells. Methods of use of the described chimeric proteins are also provided herein.Type: ApplicationFiled: January 24, 2022Publication date: July 7, 2022Inventors: Alexander LEVITZKI, Yael Langut, Nufar Edinger
-
Patent number: 11298376Abstract: A method of treating cancer can include administering a polyplex of a double stranded RNA and a polymeric conjugate. The polymeric conjugate can consist of a linear polyethyleneimine covalently linked to one or more polyethylene glycol (PEG) moieties. Each PEG moiety can be conjugated via a linker to a targeting moiety capable of binding to a cancer antigen.Type: GrantFiled: March 7, 2019Date of Patent: April 12, 2022Assignee: TARGIMMUNE THERAPEUTICS AGInventors: Alex Levitzki, Salim Joubran, Alexei Shir, Maya Zigler, Alaa Talhami, Yael Langut
-
Patent number: 11230580Abstract: Described herein are recombinant chimeric proteins comprising a double stranded RNA (dsRNA) binding domain and a cancer-cell targeting domain for targeting of dsRNA to cancer cells. Methods of use of the described chimeric proteins are also provided herein.Type: GrantFiled: March 8, 2018Date of Patent: January 25, 2022Assignee: TARGIMMUNE THERAPEUTICS AGInventors: Alexander Levitzki, Yael Langut, Nufar Edinger
-
Publication number: 20200230248Abstract: The present invention relates to a polyplex for use in the treatment of castration resistant prostate cancer (CRPC) comprising a double stranded RNA (dsRNA) and a polymeric conjugate, wherein said polymeric conjugate consists of a linear polyethyleneimine (LPEl), one or more polyethylene glycol (PEG) moieties, one or more linkers and one or more targeting moieties, wherein said LPEl is covalently bound to one or more PEG moieties and each of said one or more PEG moieties is conjugated via one of the one or more linkers to one of the one or more targeting moieties, wherein each of said one or more targeting moieties is capable of binding to a cancer antigen, and wherein said cancer antigen is prostate surface membrane antigen (PSMA). Further, the invention relates to a pharmaceutical composition for use in the treatment of CRPC.Type: ApplicationFiled: September 27, 2018Publication date: July 23, 2020Inventors: Esteban POMBO-VILLAR, Alexander LEVITZKI, Yael LANGUT, Maya ZIGLER, Alexei SHIR, Eric KITAS
-
Patent number: 10543232Abstract: A polyplex of a double stranded RNA (dsRNA) and a polymeric conjugate consists of a linear polyethyleneimine (PEI) covalently linked to one or more polyethylene glycol (PEG) moieties. Each PEG moiety is conjugated via a linker to a targeting moiety capable of binding to a cancer antigen. Exemplary cancer antigens include epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2) and prostate surface membrane antigen (PSMA).Type: GrantFiled: March 8, 2019Date of Patent: January 28, 2020Assignee: TargImmune Therapeutics AGInventors: Alex Levitzki, Salim Joubran, Alexei Shir, Maya Zigler, Alaa Talhami, Yael Langut
-
Publication number: 20190262395Abstract: A method of treating cancer can include administering a polyplex of a double stranded RNA and a polymeric conjugate. The polymeric conjugate can consist of a linear polyethyleneimine covalently linked to one or more polyethylene glycol (PEG) moieties. Each PEG moiety can be conjugated via a linker to a targeting moiety capable of binding to a cancer antigen.Type: ApplicationFiled: March 7, 2019Publication date: August 29, 2019Inventors: Alex Levitzki, Salim Joubran, Alexei Shir, Maya Zigler, Alaa Talhami, Yael Langut
-
Publication number: 20190192563Abstract: A polyplex of a double stranded RNA (dsRNA) and a polymeric conjugate consists of a linear polyethyleneimine (PEI) covalently linked to one or more polyethylene glycol (PEG) moieties. Each PEG moiety is conjugated via a linker to a targeting moiety capable of binding to a cancer antigen. Exemplary cancer antigens include epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2) and prostate surface membrane antigen (PSMA).Type: ApplicationFiled: March 8, 2019Publication date: June 27, 2019Inventors: Alex Levitzki, Salim Joubran, Alexei Shir, Maya Zigler, Alaa Talhami, Yael Langut
-
Publication number: 20190194282Abstract: Described herein are recombinant chimeric proteins comprising a double stranded RNA (dsRNA) binding domain and a cancer-cell targeting domain for targeting of dsRNA to cancer cells. Methods of use of the described chimeric proteins are also provided herein.Type: ApplicationFiled: December 15, 2016Publication date: June 27, 2019Inventors: Alexander LEVITZKI, Yael LANGUT
-
Patent number: 10278991Abstract: A polyplex of a double stranded RNA and a polymeric conjugate is provided, wherein the polymeric conjugate consists of a linear polyethyleneimine covalently linked to one or more polyethylene glycol (PEG) moieties, each PEG moiety being conjugated via a linker to a targeting moiety capable of binding to a cancer antigen.Type: GrantFiled: May 14, 2015Date of Patent: May 7, 2019Assignee: TARGIMMUNE THERAPEUTICS AGInventors: Alex Levitzki, Salim Joubran, Alexei Shir, Maya Zigler, Alaa Talhami, Yael Langut
-
Publication number: 20180346596Abstract: Described herein are recombinant chimeric proteins comprising a double stranded RNA (dsRNA) binding domain and a cancer-cell targeting domain for targeting of dsRNA to cancer cells. Methods of use of the described chimeric proteins are also provided herein.Type: ApplicationFiled: March 8, 2018Publication date: December 6, 2018Inventors: Alexander LEVITZKI, Yael Langut, Nufar Edinger
-
Publication number: 20170072063Abstract: A polyplex of a double stranded RNA and a polymeric conjugate is provided, wherein the polymeric conjugate consists of a linear polyethyleneimine covalently linked to one or more polyethylene glycol (PEG) moieties, each PEG moiety being conjugated via a linker to a targeting moiety capable of binding to a cancer antigen.Type: ApplicationFiled: May 14, 2015Publication date: March 16, 2017Inventors: Alex Levitzki, Salim Joubran, Alexei Shir, Maya Zigler, Alaa Talhami, Yael Langut
-
Patent number: 8399026Abstract: The presently described subject matter relates to isolated spider venom peptides, which are used as potent and selective ion channel blockers, and to a composition and methods for treatment of pain.Type: GrantFiled: September 14, 2010Date of Patent: March 19, 2013Assignee: Alomone Preclinical Ltd.Inventors: Alon Meir, Ronit Simcha Cherki, Ela Kolb, Yael Langut, Nissim Bajayo
-
Publication number: 20110065647Abstract: The presently described subject matter relates to isolated spider venom peptides, which are used as potent and selective ion channel blockers, and to a composition and methods for treatment of pain.Type: ApplicationFiled: September 14, 2010Publication date: March 17, 2011Applicant: BIOSEARCH (2007) LTD.Inventors: Alon MEIR, Ronit Simcha CHERKI, Ela KOLB, Yael LANGUT, Nissim BAJAYO